New molecular entity
Development and Regulatory status
Phase III Clinical Trials
A fully recombinant blood factor, using XTEN technology, that comprises a large polypeptide that inhibits renal clearance and may inhibit receptor mediated clearance for some molecules
It affects 1:4,000 to 1:5,000 live male births worldwide. It is five times as common as haemophilia B .